chikungunya virus

Valneva reports latest findings from chikungunya vaccine trial
Valneva reports latest findings from chikungunya vaccine trial
Clinical Trials Arena
Valneva
chikungunya virus
Ixchiq
clinical trials
Flag link:
Valneva single-dose chikungunya vaccine poised to ‘revolutionize’ global health
Valneva single-dose chikungunya vaccine poised to ‘revolutionize’ global health
Biopharma Reporter
Valneva
vaccines
Ixchiq
FDA
chikungunya virus
Flag link:
FDA approves Valneva's chikungunya vaccine
FDA approves Valneva's chikungunya vaccine
Reuters
Valneva
vaccines
chikungunya virus
FDA
Ixchiq
Flag link:
Valneva reports data from chikungunya vaccine trial in adolescents
Valneva reports data from chikungunya vaccine trial in adolescents
Clinical Trials Arena
Valneva
clinical trials
VLS1553
chikungunya virus
Flag link:
FDA, seeking time for phase 4 talks, delays decision on Valneva's chikungunya vaccine by 3 months
FDA, seeking time for phase 4 talks, delays decision on Valneva's chikungunya vaccine by 3 months
Fierce Biotech
Valneva
vaccines
FDA
chikungunya virus
Flag link:
Bavarian Nordic goes 2 for 2 in pivotal chikungunya vaccine trials, teeing up filing to rival Valneva
Bavarian Nordic goes 2 for 2 in pivotal chikungunya vaccine trials, teeing up filing to rival Valneva
Fierce Biotech
Bavarian Nordic
chikungunya virus
vaccine
clinical trials
Valneva
Flag link:
Bavarian Nordic bites back in chikungunya vaccine race, hitting phase 3 goal to stay on Valneva's heels
Bavarian Nordic bites back in chikungunya vaccine race, hitting phase 3 goal to stay on Valneva's heels
Fierce Biotech
Bavarian Nordic
clinical trials
chikungunya virus
vaccines
Valneva
Flag link:
Valneva Reports Strong Phase III Chikungunya Vaccine Data After Merck’s Exit from Race
Valneva Reports Strong Phase III Chikungunya Vaccine Data After Merck’s Exit from Race
BioSpace
Valneva
chikungunya virus
clinical trials
vaccines
Flag link:
FDA accepts Valneva’s chikungunya vaccine BLA for priority review
FDA accepts Valneva’s chikungunya vaccine BLA for priority review
Pharmaceutical Business Review
Valneva
chikungunya virus
vaccine
VLS1553
Flag link:
Emergent scores a DoD award to evaluate its chikungunya vaccine in the field
Emergent scores a DoD award to evaluate its chikungunya vaccine in the field
Endpoints
Emergent BioSolutions
chikungunya virus
Department of Defense
government contracts
vaccines
Flag link:
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development
BioSpace
Merck
Emergent BioSolutions
Affinivax
Ocugen
vaccines
chikungunya virus
pneumococcal disease
COVID-19
Flag link:
Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
BioSpace
Valneva
vaccines
clinical trials
VLA1553
chikungunya virus
Flag link:
Moderna scraps lead mRNA chikungunya candidate after phase 1, slowing push beyond prophylactic vaccines
Moderna scraps lead mRNA chikungunya candidate after phase 1, slowing push beyond prophylactic vaccines
Fierce Biotech
Moderna Therapeutics
vaccines
MRNA
chikungunya virus
clinical trials
Flag link:
Chikungunya vaccine candidate enters Phase 2/3 trial
Chikungunya vaccine candidate enters Phase 2/3 trial
BioPharma Dive
vaccines
Bharat Biotech
clinical trials
chikungunya virus
Flag link:
Valneva’s chikungunya vaccine reports positive topline data from Phase 3 trial
Valneva’s chikungunya vaccine reports positive topline data from Phase 3 trial
Biopharma Reporter
Valneva
vaccines
chikungunya virus
clinical trials
Flag link:
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
Drugs.com
Emergent BioSolutions
clinical trials
vaccines
chikungunya virus
Flag link:
Themis raises €40M to run phase 3 chikungunya vaccine trial
Themis raises €40M to run phase 3 chikungunya vaccine trial
Fierce Biotech
Themis
Merck
chikungunya virus
vaccines
clinical trials
Flag link:
Moderna announces dosing of first monoclonal antibody encoded by mRNA in clinical trial
Moderna announces dosing of first monoclonal antibody encoded by mRNA in clinical trial
Pharmaceutical Business Review
Moderna Therapeutics
MRNA
mRNA-1944
clinical trials
chikungunya virus
Flag link:
Themis pulls out of IPO, looks into 'strategic options' to fund phase 3 vaccine trial
Themis pulls out of IPO, looks into 'strategic options' to fund phase 3 vaccine trial
Fierce Biotech
Themis Bioscience
IPOs
Amsterdam
chikungunya virus
Flag link:
FDA adds four tropical diseases to Priority Review voucher program
FDA adds four tropical diseases to Priority Review voucher program
BioCentury
FDA
priority review vouchers
tropical diseases
chikungunya virus
rabies
cryptococcal meningitis
Lassa fever
Flag link:

Pages